Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

In part of one of this series, we analyzed the discussions surrounding using cannabis for mental health. In part two, we took a deep look at using cannabis for depression. In part three, we will analyze the available research concerning cannabis and anxiety. Can you use cannabis for anxiety? Cannabis and Anxiety.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

SEPTEMBER 29, 2022

Australia’s drugs regulator issues 73 infringement notices over claims prescriptions could treat conditions such as cancer and epilepsy. The Therapeutic Goods Administration (TGA) issued 73 infringement notices totalling $972,360 between the medicinal cannabis companies MGC Pharmaceuticals Ltd, Cannatrek Ltd and Little Green Pharma Ltd.

Epilepsy 52

Epilepsy Conditions Media Medicine 52

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. Studies have suggested that CBD may help manage chronic pain, reduce anxiety and depression, alleviate symptoms of epilepsy, and even aid in cancer treatment.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

JULY 30, 2019

Following an encouraging initial US launch, GW Pharmaceuticals’s cannabidiol oral solution is also set to achieve European approval later in 2019. Knowledge, attitudes and policies regarding medical cannabis and cannabis-based drugs are changing. Cannabidiol-based treatment receives marketing approval from EMA.

Epilepsy 40

Epilepsy Pharmaceutical Medicine Treatment 40

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. Medical cannabis costs family £4,000 a month to help teenager.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

AUGUST 17, 2021

.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. We look forward to initiating our Phase 3 trial and adding to the body of evidence that supports ganaxolone’s potential as an innovative treatment option for rare epilepsies.”. Chief Medical Officer of Marinus. “We Data Highlights.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

Cannabis Law Report

JANUARY 15, 2019

British firm GW Pharmaceuticals is licking its wounds after US judges tossed out its attempt to patent multiple cannabinoids for epilepsy treatment following an eight-year battle. The patent, which has been embroiled in dispute since 2010, is for “the use of one or more cannabinoids in the treatment of epilepsy”.

Epilepsy 71

Epilepsy Cannabinoids Treatment Research and Development 71

Cannabis Law Report

JUNE 5, 2019

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. 30 May 2019.

Pharmaceutical 40

Pharmaceutical Extraction Epilepsy Research and Development 40

MMJ Recs

NOVEMBER 17, 2023

By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. Support for Patient Well-Being The availability of medical marijuana in local communities fosters an environment of support for patients seeking alternative treatments.

Chronic Pain 98

Chronic Pain Therapy Research and Development Treatment 98

Cannabis Law Report

DECEMBER 11, 2021

A Manchester MP’s bid to open up cannabis treatments on the NHS has been blocked by Tory backbenchers in the House of Commons. 'A Despite the Government legalising medicinal cannabis in 2018, following a number of high-profile campaigns, thousands of people are still being denied access to the treatment.

Treatment 52

Treatment Access Patients Medicine 52

Cannabis Law Report

SEPTEMBER 28, 2021

Acupuncture is one of the safest alternative forms of treatment for chronic pain. Ideally, it should be used in combination with other therapies, such as herbal medicine and massage, and can be a great addition to other treatments. Radio Frequency Treatment. Acupuncture. First, you need to find a certified acupuncturist.

Treatment 52

Treatment Chronic Pain Therapy Tincture 52

Veriheal

JULY 26, 2023

Georgia medical cannabis patients will soon have greater access to treatment as cannabis oil will be sold in many more pharmacies. The Georgia State Board of Pharmacy recently made the decision to endorse more cannabis oil sale outlets. Its conversion into low-THC cannabis oil also allowed for treating many diseases.

Oil 98

Oil Patients Access THC 98

WeedAdvisor

JANUARY 8, 2019

For decades, marijuana for cancer treatment seemed out of the question. Even if trials were successful, it is safe to say that using marijuana to treat cancer would meet resistance from the pharmaceutical companies and medical communities alike. But with countries like Canada and Uruguay have legalized cannabis entirely, and the U.S.

Treatment 75

Treatment Research and Development Cannabinoids THC 75

Cannabis Law Report

AUGUST 24, 2021

BALTIMORE–(BUSINESS WIRE)– $MYMD — MyMD Pharmaceuticals, Inc. “Nearly 100,000 people in the United States have idiopathic pulmonary fibrosis (IPF), and although cases continue to climb, there is still a significant unmet need in treatment options for this chronic disease,” said Chris Chapman, M.D.,

Pharmaceutical 98

Pharmaceutical Clinical Trials Chronic Pain CBD 98

Cannabis Law Report

JANUARY 16, 2022

The government will review the Dangerous Drugs Act 1952 and the Poisons Act 1952 to regulate cannabis and ketum for medical use, Health Minister Khairy Jamaluddin said. Cannabis, or marijuana, is currently banned under the Dangerous Drugs Act that imposes extremely harsh penalties for the use of illegal narcotics.

Research and Development 98

Research and Development Pharmaceutical Epilepsy Medicine 98

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

MGC Pharma

APRIL 4, 2018

A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals. CBD-based treatment for people with Refractory Epilepsy?—?is Refractory Epilepsy is epilepsy that involves frequent and severe seizures that are difficult to treat. CannEpil™?—?CBD-based

Epilepsy 100

Epilepsy Pharmaceutical Research and Development CBD 100

MGC Pharma

NOVEMBER 1, 2017

This is a big moment for me and the MGC Pharmaceuticals team. Needless to say, I have been waiting a long time to write the following sentence: MGC Pharmaceuticals has just released their first product to the market. CannEpil™ is CBD-based medication that is used as a treatment for people with refractory epilepsy.

Epilepsy 100

Epilepsy Pharmaceutical Medicine CBD 100

United Patients Group

APRIL 18, 2023

Introduction The medical cannabis industry is booming. However, there are still many myths about cannabis that persist despite being debunked by medical professionals and researchers alike. Myth: Cannabis is just a drug. Cannabis is a plant. Myth: Cannabis is a gateway to other drugs. Myth: Cannabis is a cure-all.

Research and Development 108

Research and Development Indica Treatment Conditions 108

Cannabis Law Report

JULY 7, 2022

Eleven of thirteen cannabis patent claims survive PTAB challenge. filed a petition requesting inter partes review of claims 1-13 of GW Pharmaceutical Ltd.’s s patent directed to the use of cannabinoids, including cannabidiol (“CBD”), in the treatment of certain types of epilepsy. January 2019. IPR2017-00503, Paper No.

Epilepsy 52

Epilepsy Pharmaceutical Treatment Cannabinoids 52

Cannabis Law Report

AUGUST 4, 2022

Following the keenly anticipated June approval of its cannabis-derived Epidiolex, GW Pharmaceuticals $GWPH has finally launched the rare epilepsy drug in the United States. Epidiolex is sourced from natural cannabis grown by the British drugmaker in the United Kingdom.

Epilepsy 52

Epilepsy Therapy Patients Treatment 52

MMJ Recs

FEBRUARY 18, 2024

As society re-evaluates its stance on cannabis, a growing body of research is uncovering the therapeutic potential of this plant. Image by Ryan Lange on Unsplash Therapeutic Potential of Cannabis The therapeutic potential of cannabis lies in its ability to alleviate symptoms and improve overall health.

Chronic Pain 52

Chronic Pain Marijuana Epilepsy Research and Development 52

Cannabis Law Report

NOVEMBER 5, 2019

Cabot Wealth Management Inc increased its stake in Gw Pharmaceuticals Plc (GWPH) by 34.2% The institutional investor held 20,865 shares of the major pharmaceuticals company at the end of 2019Q2, valued at $3.60M, up from 15,548 at the end of the previous reported quarter. based on its latest 2019Q2 regulatory filing with the SEC.

Pharmaceutical 45

Pharmaceutical Epilepsy Treatment Medicine 45

Veriheal

SEPTEMBER 16, 2020

Though cannabis is becoming increasingly legal across the nation, both for recreational and medical purposes, there’s no sign that the US government intends to legalize cannabis on the federal level. This causes complications as more people than ever before are exploring cannabis for medical purposes. What is Epidiolex?

Access 98

Access Epilepsy Treatment Conditions 98

Cannabis Law Report

AUGUST 20, 2021

Swiss Life Sciences Group Plc (SLSG) is pleased to announce its partnership with Switzerland’s leading cannabis and CBD genetics experts, Bio Zu Farm , who have been developing their own cannabis genetics for more than 25 years. This fits with our own strong values and commercial objectives.

Research and Development 116

Research and Development Strains Treatment Epilepsy 116

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

Veriheal

FEBRUARY 21, 2023

As medicinal and recreational cannabis legalization continues to sweep across the United States, a recent study paints a concerning portrait of many states denying or restricting medical marijuana (MMJ) access. Why Do MMJ Patients Use Cannabis? How Do MMJ Restrictions Affect Patients and Doctors?

Access 98

Access Patients Chronic Pain Conditions 98

MGC Pharma

DECEMBER 12, 2017

A word from Elad Segev, Manager of Breeding and Cultivation at MGC Pharmaceuticals. A Cannabis plant is made up of 400 different chemicals that have physical and psychoactive effects when consumed together. Cannabinoids Many of the components found in Cannabis plants are known as cannabinoids. You can learn more about it here.

Epilepsy 100

Epilepsy Cannabinoids Pharmaceutical THC 100

Cannabis Law Report

JULY 24, 2019

Dr Mikael Sodergren , Managing Director and Academic Lead at Sapphire Medical Clinics said: “Medicinal cannabis is a new and exciting field. But it is important that access to it is delivered in a way that fits in with other treatment options.

Epilepsy 40

Epilepsy Medicine Treatment Patients 40

Cannabis Law Report

NOVEMBER 23, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Chronic Pain 52

Cannabis Law Report

SEPTEMBER 14, 2021

Depending on who you’re talking to, the plant is either an illegal and addictive narcotic, or a source of miracle treatments for everything from epilepsy, to back pain; there even some who claim it can help with depression. 33mins 24secs Is medical cannabis a wonder drug hiding in plain sight? LISTEN [link].

Medicine 52

Medicine Epilepsy Pharmaceutical History 52

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Veriheal

SEPTEMBER 27, 2021

The United Kingdom’s Multiple Sclerosis (MS) Society has taken a stand against restricted access to medical cannabis in the country. The society launched a campaign with the hashtag #ApprovedButDenied protesting the difficulty so many patients have faced attempting to obtain medical cannabis. ApprovedButDenied.

Treatment 98

Treatment Patients Access Research and Development 98

MMJ Recs

FEBRUARY 3, 2024

This guide aims to navigate the intricate web of cannabis legislation in Philadelphia, Pennsylvania, exploring key aspects such as medical marijuana laws, cannabis regulations, qualifying conditions, patient eligibility, and the overall impact on the local cannabis industry.

Legislation 52

Legislation Law Marijuana Dispensary 52

Cannabis Law Report

SEPTEMBER 13, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that it intends to initiate dosing for a Phase 2 trial of MYMD-1’s function in delaying aging early in the fourth quarter of 2021.

Clinical Trials 52

Clinical Trials Pharmaceutical Research and Development Therapy 52

TheAnswerPage

JUNE 29, 2022

Yes, GW Pharmaceuticals (the makers of Epidiolex) had trialed CBDV in adult epilepsy, but the study did not meet its primary endpoint of seizure reduction. Current controversies in medical cannabis: recent developments in human clinical applications and potential therapeutics, Neuropharmacology, [link]. Schlag, A.K.,

Clinical Trials 59

Clinical Trials Epilepsy Pharmaceutical Treatment 59

Cannabis Law Report

OCTOBER 19, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, announced today that it will present at the Dawson James Securities 6th Annual Small Cap Growth Conference on Thursday, October 21, 2021, at 4:30 p.m.

Pharmaceutical 52

Pharmaceutical Therapy Clinical Trials Chronic Pain 52